KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $110.6 million.

  • Amneal Pharmaceuticals' Cash & Equivalents rose 171.94% to $201.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.2 million, marking a year-over-year increase of 171.94%. This contributed to the annual value of $110.6 million for FY2024, which is 20.77% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Cash & Equivalents is $110.6 million, which was up 20.77% from $91.5 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash & Equivalents peaked at $341.4 million during FY2020, and registered a low of $26.0 million during FY2022.
  • Over the past 3 years, Amneal Pharmaceuticals' median Cash & Equivalents value was $91.5 million (recorded in 2023), while the average stood at $76.0 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Cash & Equivalents plummeted by 89.52% in 2022 and then surged by 252.41% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Cash & Equivalents stood at $341.4 million in 2020, then decreased by 27.41% to $247.8 million in 2021, then plummeted by 89.52% to $26.0 million in 2022, then spiked by 252.41% to $91.5 million in 2023, then increased by 20.77% to $110.6 million in 2024.